Evaluating Clinical Pathways for Ovarian Cancer Treatment and Maintenance Therapy

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Ongoing Clinical Trials with PARP Inhibitors in Ovarian CancerПодробнее

Maintenance Therapy Options for Ovarian CancerПодробнее

Navigating Rapid Change in Ovarian Cancer: PARP Inhibitors in Clinical PathwaysПодробнее

ESHRE Guidelines: Management of Women with EndometriosisПодробнее

Utilizing Clinical Pathways for Remission Maintenance in Ovarian CancerПодробнее

Zuventus Webinar | Latest Medical Insights & Treatment Strategies | 25th June 2022Подробнее

Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancerПодробнее

Maintenance Therapy in Ovarian CancerПодробнее

Practice-Changing Updates in Ovarian Cancer: Implications for Pathways ConstructionПодробнее

The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian CancerПодробнее

Biomarker-Driven Frontline Ovarian Cancer TreatmentПодробнее

PARP Inhibitors for Maintenance Therapy in Ovarian CancerПодробнее

Did you know Ovarian Cancer affects more than just ovaries? | AOI.Подробнее

Updates in Ovarian Cancer: Frontline MaintenanceПодробнее

Ovarian Cancer Patient has Extraordinary Response to Clinical Trial TreatmentПодробнее

Localising ovarian cancer pathways in a regional setting Ms Lisa Delaney, Northern NSW Cancer InstitПодробнее

Ovarian Cancer: Standards of Care and New Opportunities - Dr. Robert ColemanПодробнее

Treatments for Recurrent Ovarian CancerПодробнее

Dr. O’Malley on Ongoing Clinical Trials Evaluating Immunotherapy in Ovarian CancerПодробнее